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Abstract
Chronic radiation proctitis (CRP), characterized by increased frequency and
urgency of defecation, fecal incontinence and rectal bleeding, is an under-estimated
cause of morbidity after pelvic irradiation for urological and gynecological malig-
nant diseases. Despite improvements in radiotherapy technology, 90% of patients
have persistent long term symptoms and 50% of all patients report impairment of
quality of life after pelvic radiotherapy. Research by an Australian group of clinician
scientists, including prospective, longitudinal and retrospective studies as well as a
randomized trial of two current approaches used for the treatment of haemorrhagic
radiation proctitis over a time span exceeding two decades, have provided impor-
tant insights into the prevalence, pathophysiology natural history and treatment of
CRP. The findings have important implications for the management and ameliora-
tion if not prevention of CRP. Data from 4 selected studies conducted by the
Australian group, each characterizing changes in anorectal function and anal
sphincteric morphology, are first presented. This is followed by discussion of how
the findings have led to the development of more rational therapeutic interventions
for CRP and how novel approaches designed to reduce the prevalence of CRP when
combined could lead to its elimination in the foreseeable future.
Keywords: Pelvic cancer, radiotherapy, anorectal physiology, haemorrhagic
proctitis, quality of life
1. Introduction
Among the estimated 300,000 patients per year worldwide undergoing radio-
therapy for pelvic malignant diseases such as carcinoma of the uterine cervix and
corpus, bladder and prostate, nine out of 10 will develop a permanent change in
their bowel habit [1]. Furthermore, this UK group and an Australian group of
clinician scientists have independently reported that 50% of all patients report an
adverse impact on activities of daily living (ADL) after pelvic radiotherapy [1, 2].
The radiation induced bowel symptoms which have the greatest adverse effect
on ADL are anorectal symptoms such as increased frequency and urgency of defe-
cation, fecal incontinence and rectal bleeding collectively referred to as Chronic
Radiation Proctitis (CRP) [1–3].
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The prevalence of CRP is uncertain. Studies using physician based question-
naires such as the Radiation Therapy Oncology Group (RTOG) scales report a
prevalence of only 5–10% [4]. However, because these scales do not evaluate com-
mon anorectal symptoms such as urgency of defecation and fecal incontinence,
physician based scales probably under-estimate the prevalence of CRP. In support
of this, studies that have included patient-based questionnaires such as the Late
Effect Normal Tissue – Subjective Objective Management Analytic (LENT –
SOMA) scales have reported that up to 78% of patients have persistent anorectal
symptoms after radiotherapy for prostate carcinoma [5–9]. Although persistent
anorectal symptoms impair the daily activities of 50% of all patients 5 years after
pelvic radiotherapy, the pathophysiology of anorectal dysfunction has not been
fully characterized and its treatment is unsatisfactory. Previous physiological stud-
ies in patients with anorectal dysfunction after radiotherapy have been limited
either by methodological inadequacies [10] or lack of follow-up studies beyond
2 years [11, 12].
The rationale for the selection of each of the 4 listed studies for discussion in this
chapter are provided under the sub-headings below:
1.Pathophysiology and natural history of anorectal sequelae following radiation
therapy for carcinoma of the prostate [2]
In view of the limitations of previous physiological studies of anorectal
function after radiotherapy for prostate carcinoma, 5 year data from an
Australian prospective, longitudinal study of a subset of patients who
participated in a Phase III randomized trial comparing a 4 week course of
(hypofractionated) radiotherapy with the then conventional 6.5 week schedule
of radiotherapy for carcinoma of the prostate [13] will first be presented.
2.A retrospective study of the effects of pelvic irradiation for gynecological
cancer on anorectal function [14])
As at least a third of patients, who have had pelvic radiotherapy for
gynecological cancer are reported to suffer significant radiation bowel sequelae
[1], anorectal function data from the above retrospective study will be
presented next.
3.Argon Plasma Coagulation Therapy versus Topical Formalin for intractable
rectal bleeding and anorectal dysfunction after radiation therapy for prostate
carcinoma [15]
As rectal bleeding is the second most common reason for referral to a
gastroenterologist after pelvic radiotherapy even though it impairs the ADL’s
of only 6% of patients [1], data from the only randomized trial of two current
approaches used in the treatment of haemorrhagic radiation proctitis above
will follow.
4.Pudendal nerve injury impairs anorectal function and health related quality of
life measures ≥2 years after 3D conformal radiotherapy for prostate cancer
[16]
Previous studies of the pathophysiology of anorectal dysfunction after
radiotherapy for carcinoma of the prostate including our own have implicated
weakness of the external anal sphincter (EAS) and internal anal sphincter
(IAS), decreased rectal compliance, increased rectal sensitivity and faster
distal colonic transit [2, 17, 18]. The underlying pathogenesis proposed for the
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observed changes in anorectal dysmotility is either myogenic or neurogenic.
However, as muscle tissue particularly striated muscle constituting the EAS is
more resistant to radiation damage than neural tissue [2], evidence of
pudendal nerve injury after radiotherapy for prostate cancer is presented in
the above study [16]. In addition, the editorial accompanying the publication
states that the findings show the way forward for the restoration of bowel
health of patients who have been adversely affected following pelvic
radiotherapy for urological and gynecological malignant diseases [19].
2. Eligibility criteria, experimental protocol, data presentation and
interpretation of the studies selected for presentation in this chapter
2.1 Pathophysiology and natural history of anorectal sequelae following
radiation therapy for carcinoma of the prostate [2]
2.1.1 Subject selection criteria
The 34 patients, median age = 68 (range 54–79) years, selected for the above
study met the following eligibility criteria:
i. Were part of the 217 total patient population participating in a previous
Phase III randomized trial of two radiation dose schedules [13]
ii. Have completed (7) serial evaluations (before radiotherapy, at 1 month and
at 1 yearly intervals to 5 years after completion of radiotherapy) of
anorectal function using the same manometric assembly
iii. Have not needed treatment intervention likely to influence anorectal
function such as a constant requirement for antidiarrhoeal medication and
argon plasma coagulation therapy (APC) for rectal bleeding
iv. Have provided signed informed consent
Of the total patient population of 217 patients, 86 patients (57 completed two
serial evaluations of anorectal function using an earlier manometric assembly which
meant that later serial measurements were no longer comparable, 5 started radio-
therapy before baseline evaluation and 24 patients died before 5 years), failed to
meet eligibility criterion (ii), 12 patients, who required APC for rectal bleeding after
radiotherapy, failed eligibility criterion (iii) and 85 patients, who withdrew consent
for anorectal manometry after radiotherapy because of distant domicile from the
laboratory, failed eligibility criterion (iv).
2.1.2 Experimental protocol
Each of the 34 patients meeting all eligibility criteria for the study underwent
evaluations of (i) gastrointestinal symptoms (modified LENT-SOMA scales includ-
ing effect on activities of daily living (ADL), (ii) anorectal motor and sensory
function (manometry with a perfused sleeve and multiport assembly incorporating
a highly compliant polyethylene bag in the rectum) and (iii) anal sphincteric mor-
phology (endoanal ultrasound) before radiotherapy and at 1 month, then yearly for
5 years after completion of radiotherapy.
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2.1.3 Data presentation and interpretation
Total GI symptom scores increased after radiotherapy and remained above
baseline levels at 5 years (Table 1). At this time, 48% of patients reported impair-
ment of ADL [2].
The prevalence of persistent urgency of defaecation (44%) was doubled that of
rectal bleeding (21%) at 5 years. The % of patients free from the risk of urgency of
defecation was significantly less than that of rectal bleeding (Figure 1).
All measures of anorectal motor function remained below baseline levels at
5 years (Table 2). Furthermore, anal pressures in response to voluntary squeeze and
increased intra-abdominal pressure progressively decreased after radiotherapy.
The volume for first perception of rectal distension and that associated with the
desire to defaecate both decreased after radiotherapy although only threshold
Baseline 1 mo 1 y 2 y 3 y 4 y 5 y ANOVA
P value
Stool frequency 0(0–2) 1(0–2) 1(0–2) 1(0–2) 1(0–1) 1(0–2) 1(0–1) 0.05
Stool Consistency 0(0–1) 0(0–2) 0(0–2) 0(0–2) 0(0–2) 0(0–1) 0(0–2) ns
Rectal Pain 0(0–1) 0(0–3) 0(0–1) 0(0–1) 0(0–1) 0(0–1) 0(0–2) < .01
Rectal mucous
discharge
0(0–2) 0(0–4) 0(0–3) 0(0–3) 0(0–3) 0(0–3) 0(0–3) < .01
Urgency of
defecation
0(0–3) 0(0–4) 1(0–3) 1(0–3) 1(0–4) 1(0–3) 1(0–3) ns
Rectal bleeding 0(0–2) 0(0–2) 0(0–2) 0(0–3) 0(0–3) 0(0–2) 0(0–4) ns
Total GI symptom 2(0–4) 3(0–10) 3(0–9)* 3(0-9)* 3(0-7)† 3(0–9)* 3(0-9)* < .01
Abbreviations: ANOVA, analysis of variance; GI, gastrointestinal; ns, not significant.
*P < .05 Compared with baseline.
†P < .01 Compared with baseline.
From Yeoh et al. [2], with permission.
Table 1.
Median (range) anorectal symptoms at baseline and 1 month, annually to 5 years after radiation therapy for
prostate carcinoma.
Figure 1.
Percent of patients free from urgency of defaecation vs. rectal bleeding 5 years after radiation therapy.
GI = gastrointestinal. (From Yeoh et al. [2], with permission).
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Baseline 1 mo 1 y 2y 3y 4y 5y ANOVA P Value
Basal pressure (mm Hg) 65  3 63  3 59  3 60  3 54  3† 57  3 56  3* < .001
Squeeze Pressure (mm Hg) 128  10 126  9 106  6* 105  6† 104  5† 103  6† 99  6‡ < .0001
Increased intra-abdominal Pressure (mm Hg) 104  5 99  4 96  5 99  5 94  4 92  5 90  5* < .05
First Perception (mL) 24  2 17  1† 17  1† 15  1‡ 14  1‡ 14  1‡ 15  1‡ < .0001
Desire to defecate (mL) 63  7 44  5 58  6 40  4* 42  3 51  6 60  8 < .0001
Rectal compliance(mL) 8.2  0.6 7.4  0.5 6.8  0.7 6.2  0.8* 6.4  0.7 5.7  0.5† 5.5  0.6† <0.001
IAS thickness(mm) 2.4  0.1 2.2  0.1 2.2  0.2 2.1  0.1 2.1  0.1 2.2  01 2.3  0.1 ns
EAS thickness (mm) 10.7  0.5 11.2  0.5 11.2  0.5 10.5  0.5 10.3  0.7 9.6  0.4 9.7  0.7 Ns
Abbreviations: ANOVA, analysis of variance; EAS, external and sphincter; IAS, internal anal sphincter; ns, not significant; SE, Standard error.
*P < .05 compared with baseline.
†P < .01 compared with baseline.
‡P < .0001 compared with baseline.
From Yeoh et al. [2], with permission.
Table 2.

























































volumes for sensory perception at 5 years remained below those recorded at base-
line (Table 2). Rectal compliance progressively reduced with time after radiother-
apy and remained persistently lower at 5 years compared with that recorded at
baseline Table 2).
Radiotherapy had no effect on the thicknesses of the IAS and EAS (Table 2).
There were no differences in any of the GI symptoms nor in any anorectal
functional and anal sphincteric morphological measurements between patients ran-
domized to the 2 radiation dose schedules.
5 years after radiotherapy for carcinoma of the prostate, persistent GI symptoms
continue to have a significant impact on ADL of almost 50% of all patients. At this
time, the prevalence of urgency of defecation (44%) was doubled that of rectal
bleeding (21%). Increased GI symptoms after radiotherapy were associated with
progressive or persistent reductions of basal anal pressures and pressures in
response to voluntary squeeze and increased intra-abdominal pressures, rectal
compliance and volumes of sensory perception and desire to defaecate. These
physiological changes, which suggest weakness of the IAS and EAS as well as
stiffness of the rectal wall and consequent increased rectal sensitivity, are the
pathogenetic basis for anorectal dysfunction after radiotherapy for carcinoma of the
prostate. The etiology of the motility changes is likely to be neurogenic in the
intrinsic neural network in the bowel wall and/or extrinsic nerve supply such as the
pudendal nerves since muscle tissue, particularly striated muscle is more resistant to
radiation damage.
2.2 A retrospective study of the effects of pelvic irradiation for gynecological
cancer on anorectal function [14]
2.2.1 Subject selection criteria
The 15 patients, median age = 67 (range 47–84) years, selected for the study met
the following eligibility criteria:
i. Were part of the 33 total patient population who completed pelvic and
abdominal irradiation 5–10 years earlier for carcinoma of the cervix
(n = 30) and endometrium (n = 3) who participated in a previous
prospective longitudinal study of changes in gastrointestinal function after
pelvic radiotherapy [20]
ii. Had not needed treatment intervention likely to influence anorectal
function such as a constant requirement for antidiarrhoeal medication
iii. Had provided signed informed consent
Of the original total patient population of 33 patients, 6 had died and 2 had been
lost to follow-up since completing the previous study [20]. The 25 remaining
patients were invited to participate in this study, 10 refused including two patients
who had intermittent episodes of rectal bleeding.
9 healthy females, median age = 63 (range 41–70) years served as control subjects.
2.2.2 Experimental protocol
The following parameters were assessed in each subject: (i) anorectal symptoms
(questionnaire), (ii) anorectal motor and sensory function (manometry with a
perfused sleeve and multiport assembly incorporating a highly compliant latex
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balloon in the rectum and concurrent electromyography of the anal sphincters) and
(iii) anal sphincteric morphology (endoanal ultrasound).
2.2.3 Data presentation and interpretation
Total anorectal symptom scores was significantly greater in the patients com-
pared with the control subjects (Table 3). Urgency of defaecation was the most
frequent symptom, occurring in 10 of the 15 patients (67%). Four of these patients
also had fecal incontinence [14]. Urgency of defecation in eight of the 10 patients
resulted in changes in lifestyle such that the patients were either housebound or
could only go out if there was a toilet nearby [14].
Basal minimum pressures just proximal to the anal canal (4 cm from the anal
verge) were lower in the patients than the control subjects (p = 0.05) and there was
a trend for lower basal maximum pressures at the same site (p = 0.07, Table 4).
Squeeze pressures measured at the sleeve sensor and at 4 cm from the anal verge
were lower in the patients (p < 0.05, Table 4) and were below the control range in
five patients [14].
In the patients, residual anorectal pressures measured at 0.5 cm from the anal
verge in response to rectal distension were less (p ≤ 0.05) at volumes of 10 ml,
20 ml and 40 ml (Table 5). There was also a trend for lower pressures in the
patients at the highest (100 ml) volume (p = 0.09).
A higher proportion of patients perceived the desire to defecate at lower rectal
volumes than the controls (p < 0.05, Figure 2). The slope of the pressure/volume
relationship associated with rectal distension volumes of 20 ml, 40 ml, 60 ml,
100 ml and overall slope was greater in the patients (p < 0.05, p < 0.01, p < 0.001,
p < 0.001 and p < 0.05 respectively than the controls, suggesting that rectal
compliance was reduced in the patients (Figure 3).
There were no differences in external anal sphincteric electrical activity between
the patients and control subjects in response to voluntary squeeze and blowing up a
party balloon (Table 4). Either basal pressures, pressures generated in response to
rectal distension, voluntary squeeze and blowing up a party balloon were below the
control range in 14 of the 15 patients, including all 10 patients with anorectal
symptoms [14].
There was no difference in mean EAS and IAS thickness between the two groups
(Table 4) nor difference in thicknesses of the EAS and IAS in patients with and
without urgency of defaecation [14].
The data indicate that (i) urgency of defaecation, occurring in 10 out 15 (67%) of
patients 10–15 years after pelvic irradiation for gynecological cancer resulted in
eight of the 10 patients being either housebound or only able to go out if there was a
toilet nearby, (ii) anorectal symptoms were associated with multiple parameters of
anorectal dysfunction including weakness of the external anal sphincter, stiffness of
the rectal wall and consequent increase in rectal sensitivity.
2.3 Argon plasma coagulation therapy versus topical formalin for intractable
rectal bleeding and anorectal dysfunction after radiation therapy for
prostate carcinoma [15]
2.3.1 Subject selection criteria
The 30 patients, median age = 72 (range 49–87) years selected for the study met
the following eligibility criteria:
i. Had completed radiotherapy for prostate carcinoma ≥6 months previously
7

















Patients 3/15 1/15 10/15 10/15† 3‡(0-8) 13(13-28) 3(0–12) 4/15 3/15
Normal 0/9 0/9 1/9 1/9 0(0) 7(7–14) 3(0–4) 2/9 2/9
*Median (range).
†P < 0.01.
‡P < 0.001 Compared to normals.
From Yeoh et al. [14], with permission.
Table 3.














ii. had intractable rectal bleeding (defined as ≥1x per week and/or requiring
blood transfusions) attributed to CRP at colonoscopy
iii. had no constant requirement for medications likely to influence anorectal
motility such as opioid analgesics and anti-diarrhoeal agents
iv. Had provided signed informed consent
2.3.2 Experimental protocol
The 30 eligible patients were randomized to treatment with APC (n = 17) or
topical formalin (n = 13).
Each patient underwent evaluations of (i) anorectal symptoms (validated
questionnaires including modified LENT-SOMA scales for GI symptoms and visual
analogue scales for rectal bleeding), (ii) anorectal motor and sensory function
(manometry with a perfused sleeve and multiport assembly incorporating a highly
compliant polyethylene bag in the rectum) and (iii) anal sphincteric morphology
(endoanal ultrasound) before and after the treatment endpoint (defined as reduction
Normal Patients p-Value
EAS (mm) 8.8  0.5 9  0.4 0.78
IAS (mm) 2.8  0.2 2.3  0.2 0.65
Bmax (mmHg)
Anal 0.5 cm† 64  12.5 45.1  5.5 0.13
Sleeve 58.7  6.3 53.3  6.2 0.58
Anorectal 4 cm† 22  5.8 12.1  1.9 0.07
Bmin (mmHg)
Anal 0.5 cm† 32.2  8.2 33.1  5.0 0.93
Sleeve 44.3  5.6 41.5  5.9 0.75
Anorectal 4 cm† 14.1  3.3 8.1  1.0 0.05
Voluntary squeeze (mmHg)
Anal 0.5 cm† 108.2  21.6 70  10.0 0.08
Sleeve 103  10.2 68.1  7.2 0.01
Anorectal 4 cm† 26.4  4.6 16.3  1.8 0.03
Change EMG activity (mm) 6.7  1.8 6.2  0.8 0.75
Blowing up a party balloon
Anal 0.5 cm† 61.8  11.6 49.4  0.8 0.35
Sleeve 70.1  7.5 65.6  7.8 0.7
Anorectal 4 cm† 35.8  3.7 30.5  2.2 0.21
Change EMG activity (mm) 3.8  1.0 3.4  0.5 0.75
*Data are mean values SEM.
†Manometric port distances from anal verge.
From Yeoh et al. [14], with permission.
Table 4.
Maximum thickness of IAS and EAS and anorectal pressures (basal, in response to voluntary squeeze and
blowing up a party balloon).
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of rectal bleeding to 1x per month or better, reduction of visual analogue scales to
≤25 mm, no longer needing blood transfusions). Cross-over to the other therapy was
allowed if the treatment endpoint was not reached after 4 treatment sessions.
2.3.3 Data presentation and interpretation
Rectal bleeding was controlled in twenty nine of the 30 patients after a median
of 2 treatment sessions of APC or topical formalin. One patient, initially treated
with APC, failed after 4 treatment sessions but achieved control after 3 sessions of
cross-over topical formalin, Control of rectal bleeding was evidenced by reductions
of its frequency to ≤1x per month, VAS ≤ 25 mm (Figures 4 and 5, Table 6) and no
further requirement for blood transfusion in the 2 patients (1 each in APC and
topical formalin groups) needing this before randomization to therapy.
The durability of control of rectal bleeding by APC and topical formalin was
evidenced by only 1 patient in each group needing further therapy after a median
(range) follow-up of 111 (29–170) months [15].
No effect on other anorectal symptoms, such as increased frequency and
urgency of defecation and fecal incontinence, was observed (Table 6).
Normal Patients p-Value
RD 10
Anal 0.5 cm† 47.3  10.8 27.7  4.1 0.05
Sleeve 41.6  7.9 30.8  4.3 0.2
Anorectal 4 cm† 8.6  1.5 8.1  0.6 0.77
RD 20
Anal 0.5 cm* 40.2  5.9 24.6  3.0 0.02
Sleeve 34.2  7.5 26.7  3.4 0.31
Anorectal 4 cm† 10.4  1.9 9.1  0.7 0.44
RD 40
Anal 0.5 cm† 35.6  4.8 23.1  3.2 0.04
Sleeve 30.2  4.7 30.3  3.7 0.99
Anorectal 4 cm† 12  1.7 10.2  0.8 0.3
RD 60
Anal 0.5 cm† 43.5  12.0 29.9  7.6 0.33
Sleeve 31.1  6.0 30.9  4.0 0.98
Anorectal 4 cm† 17  2.5 12.8  1.3 0.12
RD 100
Anal 0.5 cm† 43.8  11.8 20.1  6.3 0.09
Sleeve 30.5  6.9 35.5  5.7 0.59
Anorectal 4 cm† 13.7  2.5 19  6.6 0.49
*Data are mean values  SEM.
†Manometric port distances from anal verge.
From Yeoh et al. [14], with permission.
Table 5.
Residual anorectal pressures in response to rectal distension (RD), with 10 ml, 20 ml, 40 ml, 60 ml and
100 ml*
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Other than a reduction in rectal compliance and volumes of sensory perception
after APC, no effects on parameters of anorectal function and anal sphincteric
morphology were observed (Table 7).
APC and topical formalin had comparable efficacy in the durable control of
rectal bleeding associated with chronic radiation proctitis but no beneficial effect on
anorectal dysfunction.
2.4 Pudendal nerve injury impairs anorectal function and health related quality
of life measures ≥2 years after 3D conformal radiotherapy for prostate
cancer [16]
2.4.1 Subject selection criteria
The 25 patients, median age = 76 (range 64–83) years, selected for the above
study met the following eligibility criteria:
i. Were part of 80 patients still attending follow up ≥2 years after 3D
conformal radiotherapy  high dose rate brachytherapy (HDR) for
localized prostate carcinoma under the supervision of the same tertiary
institution based Radiation Oncologist
ii. Had no clinical or radiological signs of relapse
Figure 2.
Rectal volumes at which patients and normal subjects felt desire to defaecate. (From Yeoh et al. [14], with
permission).
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Figure 3.
Pressure/volume relationship in patients and controls associated with rectal distension (from Yeoh et al. [14],
with permission).
Figure 4.
Visual analogue scale (VAS)before (pre) andafter (post)APC treatment. (FromYeoh et al. [15],with permission).
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iii. Had not needed treatment intervention likely to influence anorectal
function such as a constant requirement for antidiarrhoeal medication nor
argon plasma coagulation therapy (APC) for rectal bleeding
iv. Had provided signed informed consent
Of the 80 patients invited to participate in the study, 48 refused, 7 were ineligi-
ble (6 had APC for rectal bleeding, 1 patient had received 2D radiotherapy).
25 age matched patients with localized prostate carcinoma in a recent random-
ized radiotherapy study served as control subjects [21].
2.4.2 Experimental protocol
Each subject underwent the following evaluations: (i) GI symptoms (modified
LENT-SOMA scales), (ii) generic and disease specific HRQoL measures (EORTC
Figure 5.
Visual analogue scale (VAS) before (pre) and after (post) topical formalin treatment. (From Yeoh et al. [15],
with permission).









No. of bowel actions per week 14(4–39) 16(7–46) NS 16(3–32) 14(4–42) NS
Fecal incontinence scores 0(0–10) 0(0–4) NS 0(0–3) 0(0–2) NS
Urgency of defecation scores 3(0–6) 4(0–6) NS 4(0–6) 4(0–6) NS
Rectal bleeding scores 3(1–4) 1(0–2) .0001 3(2–4) 1(0–2) .001
VAS for rectal bleeding (mm) 52(22–75) 14(0–34) .05 50(32–100) 13(0–25) .01
Abbreviations: NS, not significant; VAS, visual analogue scale; Values are median (range).From Yeoh et al. [15],
with permission.
Table 6.
Effect on anorectal symptom parameters of argon plasma coagulation therapy (APC) and topical formalin
treatment.
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QLQ-C30 and EORTC QLQ-PR25 questionnaires), (iii) anorectal motor and sensory
function (manometry with a perfused sleeve and multiport assembly incorporating
a highly compliant polyethylene bag in the rectum), (iv) pudendal nerve function
(terminal motor nerve latency) and (v) anal sphincteric morphology (endoanal
ultrasound).
The data of the 25 patients ≥2 years after 3D conformal radiotherapy for prostate
cancer were compared with the before radiotherapy (baseline) data of the 25 con-
trol subjects.
The data of symptomatic (defined as patients with Total LENT-SOMA GI
symptom scores ≥5, n = 13) and asymptomatic (defined as patients with Total
LENT-SOMA GI symptom scores ≤4, n = 12) patients among the 25 patients
≥2 years after 3D conformal radiotherapy were also compared.
2.4.3 Data presentation and interpretation
2.4.3.1 Comparisons of modified LENT-SOMA GI symptoms and EORTC HRQoL
measures
Patients in this study had significantly higher modified LENT – SOMA frequency
and urgency of defaecation, rectal bleeding and mucous discharge scores ≥2 years
after 3D conformal radiotherapy compared to the age matched control subjects before
radiotherapy (Table 8). The patients also had worse (lower) EORTC QLQ-C30
cognitive functioning scores and worse (higher) EORTC QLQ-PR25 bowel symptom
scores compared to the controls before radiotherapy (Table 8).
Symptomatic patients had significantly higher (i) modified LENT SOMA
urgency of defaecation and rectal bleeding scores and (ii) EORTC QLQ-PR25 bowel
and urinary symptom scores compared with asymptomatic patients (Table 9).
Symptomatic patients also had worse (lower) EORTC QLQ-C30 social and emo-
tional functional as well as global health scores compared to asymptomatic patients
(Table 9).











Basal pressure (mm Hg) 52  4 58  2 NS 58  5 51  3 NS
Squeeze pressure (mm Hg) 95  8 100  9 NS 97  6 89  6 NS
Increased intra-abdominal pressure
(mm Hg)
85  4 88  6 NS 87  6 92  6 NS
Threshold of perception pressure
(mm Hg)
16  1 17  1 NS 18  2 19  2 NS
Threshold of perception volume
(mL)
19  2 14  1 .05 17  3 14  1 NS
Desire to defecate (mL) 61  10 48  5 NS 45  11 47  9 NS
Rectal compliance (mm Hg/mL) 4.2  0.4 3.3  0.4 .01 8.1  2.6 4.3  0.7 NS
IAS thickness (mm) 2.4  0.1 2.2  0.1 NS 2.4  0.1 2.4  0.2 NS
EAS thickness (mm) 10.0  0.5 10.5  0.5 NS 11.5  0.6 11.2  0.6 NS
Abbreviations: NS, not significant; EAS, external anal sphincter; IAS, internal anal sphincter; Values are
mean  SE.From Yeoh et al. [15], with permission.
Table 7.
Effect on anorectal function and anal sphincteric morphology parameters of argon plasma coagulation therapy
(APC) and topical formalin treatment.
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2.4.3.2 Comparisons of anorectal and pudendal nerve function data and anal sphincter
morphology measurements
All parameters of anorectalmotor and sensory function except for threshold volumes
for sensory perceptionwere significantly worse≥2 years after 3D conformal radiother-
apy compared to agematched control subjects before radiotherapy (Table 10).
Unilateral and/or bilateral pudendal nerve responses were delayed in 13/24
(54%) of the patients compared to only 2/20 (10%) aged matched controls before






Frequency 1 (0–3) 0 (0–1) <0.01
Diarrhea 0 (0–2) 0 (0–1) ns
Pain 0 (0–2) 0 (0–2) ns
Mucous 0 (0–3) 0 (0–1) <0.05
Urgency 2 (0–4) 1 (0–2) <0.001
Bleeding 0 (0–3) 0 (0–0) <0.0001
EORTC HRQoL QLQ-C30
Physical Functioning 100 (60–100) 93 (47–100) ns
Role Functioning 100 (50–100) 100 (17–100) ns
Emotional Functioning 83 (58–100) 83 (67–100) ns
Cognitive Functioning 83 (50–100) 83 (67–100) <0.05
Social Functioning 100 (50–100) 100 (33–100) ns
Global Health Status 83 (17–100) 83 (33–100) ns
Dyspnoea 0 (0–33) 0 (0–100) ns
Insomnia 33 (0–100) 33 (0–100) ns
Appetite Loss 0 (0–33) 0 (0–33) ns
Nausea And Vomiting 0 (0–17) 0 (0–33) ns
Constipation 0 (0–67) 0 (0–67) ns
Diarrhea 0 (0–100) 0 (0–33) ns
Fatigue 22 (0–44) 22 (0–78) ns
Pain 0 (0–100) 0 (0–100) ns
Financial Difficulty 0 (0–33) 0 (0–67) ns
EORTC QLQ-PR25
Urinary Symptoms 17 (0–58) 13 (0–67) ns
Bowel Symptoms 8 (0–42) 0 (0–17) <0.01
Hormonal Treatment-Related
Symptoms
6 (0–50) 6 (0–50) ns
Abbreviations: ns, not significant; LENT-SOMA, late effect normal tissue – subjective objective management
analytic; EORTC, European Organization for Research and Treatment of Cancer; QLQ, quality of life questionnaire;
Values are median (range).From Yeoh et al. [16], with permission.
Table 8.
Comparison of modified LENT-SOMA GI symptoms and EORTC generic (QOL-C30) and disease specific
(QLQ-PR25) HRQoL data between whole patient group and age matched patients before radiotherapy.
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The thickness of both IAS and EAS was significantly less in the patients
compared to the control subjects before radiotherapy (Table 10).
Fecal incontinence scores were worse in the symptomatic compared to the
asymptomatic patients but no differences were detected in thickness of either IAS
or EAS in the patient sub-groups (Table 11).
Unilateral and/or bilateral pudendal nerve responses were delayed in 9/13 (69%)
of symptomatic compared to only 4/11 (36%) of asymptomatic patients (p
< 0.0001, data not shown).
Rectal and anal (i) V40Gy > 65%, (ii) Dmax >60 Gy, (iii) pudendal nerve Dmax
>60 Gy and (iv) Anal V60 Gy >40% were associated with a greater prevalence of
pudendal nerve function [16].
LENT-SOMA Symptomatic patients Asymptomatic patients P Value
Frequency 1(0–3) 1(0–1) ns
Diarrhea 1(0–2) 0(0–2) ns
Pain 0(0–2) 0(0–2) ns
Mucous 1(0–3) 0(0–1) ns
Urgency 3(1–4) 1(0–4) < .01
Bleeding 1(0–3) 0(0–1) < .001
EORTC QLQ-C30
Physical functioning 87(60–100) 100(73–100) ns
Role functioning 100(50–100) 100(67–100) ns
Emotional functioning 75(58–100) 96(67–100) =.05
Cognitive functioning 83(50–100) 83(67–100) ns
Social functioning 83(50–100) 100(67–100) < .001
Global health status 67(50–83) 83(17–100) < .05
Dyspnea 0(0–33) 0(0–33) ns
Insomnia 33(0–100) 33(0–33) ns
Appetite loss 0(0–33) 0(0–0) ns
Nausea of vomiting 0(0–17) 0(0–17) ns
Constipation 33(0–67) 33(0–33) ns
Diarrhea 0(0–100) 0(0–33) =.05
Fatigue 33(0–44) 11(0–33) < .05
Pain 0(0–33) 0(0–100) ns
Financial difficulty 0(0–33) 0(0–0) ns
EORTC QLQ-PR25
Urinary symptoms 25(0–58) 10(0–25) < .05
Bowel symptoms 25(8–42) 0(0–25) < .001
Hormonal treatment-related symptoms 11(0–50) 6(0–33) ns
Abbreviations: ns, not significant; LENT-SOMA, late effect normal tissue – subjective objective management
analytic; EORTC, European Organization for Research and Treatment of Cancer; QLQ, quality of life questionnaire;
Values are median (range).From Yeoh et al. [16], with permission.
Table 9.
Comparison of modified LENT-SOMA GI symptoms and EORTC generic (QOL-C30) and disease specific
(QLQ-PR25) HRQoL data between symptomatic and asymptomatic patients.
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3D radiotherapy  high dose rate brachytherapy (HDR) for localized prostate
carcinoma impairs functional measures including HRQoL, anorectal and pudendal
nerve function ≥2 years after treatment. Radiation dose constraints are proposed for
reducing the prevalence of pudendal nerve dysfunction.
3. Implications and summary of findings of studies and conclusion(s)
The data presented in this chapter, based on studies spanning over two decades
examining gastrointestinal effects of pelvic radiotherapy for prostate and
ARM Whole patient group Age matched patient group P Value
Basal pressure (mmHg) 46  4 63  3 < .01
Squeeze pressure (mmHg) 105  8 154  8 < .0001
↑Intra-abdominal pressure (mmHg) 82  5 106  5 < .01
IAS (mm) 2.1  0.1 2.6  0.1 < .05
EAS (mm) 8.0  0.3 9.3  0.3 < .01
Threshold perception (mL) 14  1 16  2 ns
Desire to defecate sensation (mL) 68  8 97  9 < .05
Rectal compliance (mL/mmHg) 3.3  0.3 5.1  0.4 < .01
FI score 2(0–8) 0(0–1) < .001
Urgency score 2(0–6) 0(0–3) < .001
Number of bowel actions/week 10.5(7–24.5) 7(3.5–21) < .05
Abbreviations: ns, not significant; IAS, internal anal sphincter; EAS, external anal sphincter; FI, fecal incontinence;
Values are mean  SE.From Yeoh et al. [16], with permission.
Table 10.
Comparison of anorectal function and anal sphincter morphology data between whole patient group and age
matched patients before radiotherapy.
ARM Symptomatic patients Asymptomatic patients P Value
Basal pressure (mmHg) 42  5 51  6 ns
Squeeze pressure (mmHg) 92  9 119  11 ns
↑Intra-abdominal pressure (mmHg) 78  7 86  8 ns
IAS (mm) 2.3  0.2 2.1  0.2 ns
EAS (mm) 8.4  0.4 7.6  0.3 ns
Threshold perception (mL) 15  2 13  1 ns
Desire to defecate sensation (mL) 55  8 81  14 ns
Rectal compliance (mL/mmHg) 3.4  0.4 3.2  0.4 ns
FI score 3(0–8) 0(0–3) < .01
Urgency score 3(0–6) 0(0–5) ns
Number of bowel actions/week 14(7–24.5) 10.5(7–17.5) ns
Abbreviations: ns, not significant; IAS, internal anal sphincter; EAS, external anal sphincter; FI, fecal incontinence;
Values are means  SE.From Yeoh et al. [16], with permission.
Table 11.
Comparison of anorectal function and anal sphincter morphology data between symptomatic and
asymptomatic patients.
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gynecological cancer, indicate that despite advances in radiotherapy technology,
anorectal dysfunction persist or progressively worsen over a period of 5–10 years
after treatment. The multiple deteriorations in anorectal function, consisting of
weakness of the anal sphincters, stiffness of the rectal wall and consequent increase
in rectal sensitivity, result in 50% of patients being housebound and only able to
go out if there is a toilet nearby. The studies also show that the prevalence of rectal
bleeding is half that of urgency of defaecation. In addition, results of the first
randomized trial of Argon Plasma Coagulation Therapy versus topical formalin for
intractable rectal bleeding after radiotherapy for prostate cancer indicate that dura-
ble control is achieved in 94–100% of patients after a median of 2 sessions of either
treatment, only 7% of patients requiring re-treatment after a median follow-up of
9 years [15]. In contrast, therapeutic options for anorectal dysfunction are limited to
medications such as loperamide and nicardipine based on pathophysiological eval-
uation of bowel disorders which include chronic radiation proctitis. For example,
nicardipine which increases the rectal threshold for desire to defecate in patients
with irritable bowel syndrome and reported to be effective in the treatment of
urgency of defecation has been proposed for the treatment of urgency of defecation
associated with chronic radiation proctitis since threshold volumes for desire to
defecate are also reduced in CRP [14]. Similarly, loperamide, by increasing basal
anal and squeeze pressures in patients with fecal incontinence of diverse aetiologies
including radiation bowel disease, has been proposed for the treatment of fecal
incontinence associated with CRP [14]. However, loperamide reduces stool bulk
potentially increasing the risk of rectal bleeding and a lower dose than that pre-
scribed for other bowel disorders is recommended [2]. Whilst the most advanced
radiation treatment technique of intensity modulated radiation therapy (IMRT) was
not used in the studies here, the prevalence of anorectal toxicity after IMRT for
prostate cancer has been reported to be 65%, worse or no different from that
reported in studies using less advanced treatment techniques including those
Figure 6.
Transverse (top) and sagittal dose distributions of IMRT plans for prostate cancer without (left) and with
(right) endorectal balloon in place. Contours: Rectal wall (green), anal wall (purple). (From Smeenk et al.
[5], with permission).
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reported here [1, 2, 6, 14, 16]. A likely explanation for the failure of IMRT to reduce
anorectal dysmotility after treatment is that its underlying pathogenesis is damage
to neural tissue in the bowel wall and/or the pudendal nerves [2, 16]. As discussed in
the editorial accompanying the published findings of the final study of this chapter
[19], the pudendal nerves are not considered as normal tissues at risk of radiation
damage and therefore could potentially receive the same if not higher doses of
radiation as the prostate target of irradiation. Radiation dose constraints for normal
tissues at risk including the pudendal nerves have been proposed (Section 2.4
above) and if applied now that IMRT has been adopted almost universally, patients
who need pelvic radiotherapy for urological and gynecological cancer can look
forward to a future free of distressing bowel morbidity. Furthermore, the daily
insertion of endorectal balloons during radiotherapy (Figure 6), which have been
shown to be very well tolerated and to further reduce radiation exposure of the
rectal and anal wall (and the anatomically closely related pudendal nerves) by IMRT
[5] means a bowel complication free cure of pelvic malignant disease can be realis-
tically achieved in the foreseeable future.
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